Background and aim: Natalizumab (NTZ) is a widely used therapy for the relapsing-remitting forms of Multiple Sclerosis (RRMS). This humanized antibody blocks the alfa-4 domain of the VLA4 integrin in leukocytes and prevents the migration of these cells to the Central Nervous System (CNS). The self-reactive lymphocytes that mediate the CNS inflammatory response remain in the periphery and apparently are regulated. Studies of regulatory T cells did not show an improved function in this population, but little is known about regulatory B cells' potential. Thus, we aim to evaluate the potential role of B cells in regulating the activated T cells from RRMS patients treated with NTZ. Methods: Healthy donors (49) and RRMS patients receiving NTZ (37) consented to participate in the study (CAAE: 99798918.0.0000.5404). Peripheral blood mononuclear cells (PBMC) were isolated and labeled for analysis by flow cytometry (FACSymphony A5 BD). CD19+ cells were purified from PBMC to perform RT-PCR. Results: The proportion of B cells (CD19+) was higher in NTZ-RRMS patients. The CD20+CD5+ B cell subset was reduced in the patients, however, these cells showed an increased anti-inflammatory profile, expressing the cytokines TGFbeta-1 and IL-27/IL-35. The expression of these molecules is one of the mechanisms by which B lymphocytes exert regulatory functions. Conclusions: Our results suggest that NTZ treatment may induce a regulatory profile in the CD20+CD5+ B lymphocytes. These cells may contribute to maintaining homeostasis in the periphery during NTZ treatment. Further, we plan to co-culture those cells with self-reactive T lymphocytes to confirm their regulatory potential. Financial support: FAPESP, CAPES, CNPq (INCT-NIM). Keywords: regulatory B cells, anti-inflammatory cytokines, relapse remitting multiple sclerosis